Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

The Super Bowl debut by digital healthcare company Hims & Hers is now listed on the injury report as questionable, following ...

Take a stroll through the aisles of any supermarket, and you will see plenty of other items, including bread, cereal bars and ...

A bold marketing move on weight-loss drugs sent HIMS stock soaring, but regulatory and industry backlash is mounting.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Days after Vancouver’s Aspect Biosystems Ltd. landed US$115 million in Series B financing in early January, CEO Tamer Mohamed likely surprised many by telling BIV that he thought the investment ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/104.-Jk-stHm.js ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...